FindTrial
Sign In

Gastric conduit perfusion assessment by ICG fluorescence in minimally invasive esophagectomy

Gastric conduit perfusion assessment by ICG fluorescence in minimally invasive esophagectomy; an exploratory study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON23045
Enrollment
20
Registered
2016-08-04
Start date
2016-09-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer, Fluorescence, NIRF, ICG

Interventions

Near-infrared fluorescence (NIRF) intra-operative imaging after administration of ICG

Sponsors

Radboud University Medical Center Nijmegen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • All patients eligible for minimally invasive esophagectomy for esophageal cancer, with gastric conduit reconstruction and intra-thoracic gastro-esophageal anastomosis • Aged 18 years or older • Providing informed consent

Exclusion criteria

Exclusion criteria: • Known pregnancy or breastfeeding • Known iodine, shellfish or ICG hypersensitivity • Known hyper-thyroidism • Known liver or renal insufficiency • Unable to provide informed consent

Design outcomes

Primary

MeasureTime frame
To explore the feasibility and added value of intra-operative NIRF imaging to assess gastric conduit perfusion in minimally invasive esophagectomy.—

Secondary

MeasureTime frame
Indentify the increase in procedure time, post-operative anastomotic leakage, patient and tumor characteristics—

Contacts

Public ContactDidi de Gouw

Radboudumc

didi.degouw@radboudumc.nlTel: 0624-3613983

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)